Page 9 - Buochs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article BUOCHS, Switzerland, March 11, 2021 /PRNewswire/ The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the population from serious illness: a pocket inhaler containing the active ingredient 2-DG (2-Deoxy-D-glucose). The DEGEGLUXID® pocket inhaler is effective both as prophylaxis and as therapy. The SARS-CoV-2 virus from the corona family is transmitted via the airways. The virus establishes itself in the respiratory tract of the infected patient, from where it infects the entire body. It is at this point that the DG-Nika AG solution takes effect: In the same way as with an asthma spray, 2-DG, a well-known molecule from the glucose family, is inhaled in tiny particles through the mouth into the

Switzerland generalPiotr kunaBarlicki university hospitalEuropean medical agencyInternal medicineMedical universityDg nika agசுவிட்சர்லாந்து ஜநரல்பையட்ர் குனாஉள் மருந்துமருத்துவ பல்கலைக்கழகம்